Is there any plans for reverse stock split on adaptimmune therapeutics?

No, there are no plans for a reverse stock split at this time for Adaptimmune Therapeutics. 1. **Recent Developments**: Adaptimmune Therapeutics has recently announced the sale of its cell therapy portfolio to US WorldMeds for $55 million. This transaction is part of a broader restructuring effort aimed at optimizing the company's operations and financial health. 2. **Stock Performance**: Following the announcement of the sale agreement, Adaptimmune's stock experienced a significant decline, trading down 65% to 12 cents per share early Monday afternoon. This drop was likely due to investor concerns about the company's future direction and the potential impact of the asset sale on its long-term prospects. 3. **Financial Situation**: The company's decision to sell its cell therapy portfolio and the subsequent stock split reflect its acute financial constraints, as highlighted by CEO Adrian Rawcliffe. Despite $180 million in annual revenue, the firm reported negative free cash flow of $110 million over the same period. 4. **Market Reaction**: The transaction is expected to close on August 4, 2025. Alongside this asset sale, Adaptimmune plans to reduce its workforce by approximately 62%, which will result in restructuring costs of $7-8 million in the third quarter of 2025. In conclusion, Adaptimmune Therapeutics is currently focused on restructuring and securing financial stability rather than implementing a reverse stock split. The company's priorities are aligned with optimizing its operations and addressing its financial constraints through strategic asset sales and workforce reductions.